Subjects first received four weeks of sunitinib, followed by fourteen days off treatment; patients then received five intradermal injections of AGS-003 every three weeks in combination with sunitinib, followed by every three months until disease progression or study end. Interim outcomes from the trial demonstrate that 81 percent of individuals experienced clinical benefit, as defined by partial response or stable disease per RECIST. AGS-003 was well tolerated, with no immunotherapy-related serious adverse events or grade 3/4 adverse events reported. Correlative immune response evaluation is normally ongoing.. Argos presents positive AGS-003 Stage 2 data for newly diagnosed advanced renal cell carcinoma at ASCO Argos Therapeutics today announced the display of positive interim data from a Phase 2 trial that evaluated the clinical activity, security and immune response of AGS-003 treatment, given in conjunction with sunitinib, in individuals with newly diagnosed advanced renal cell carcinoma .But the brand-new costs were more than offset, and the spending budget office found that the most recent version would decrease deficits by $32 billion more than the initial plan. Kaiser Health News: Roughly 23 million people would purchase health insurance through the health insurance exchanges and there will be roughly 14 million more enrollees in Medicaid and CHIP . Related StoriesYale researchers find improvements in mortality, outcomes and hospitalizations among Medicare patientsMembers signed up for Medicare Advantage satisfied with their plans, study findsApplying a top restaurant model to healthcare communications: an interview with Brandi Robinson, SanofiThe Wall structure Street Journal’s Health Blog: The CBO estimates that just $3 billion of an allotted $6 billion will end up being spent for the non-profit insurance co-ops described in the bill.